Chris Junker

As Vice President of Regulatory Sciences, my team is charged with the strategy behind and execution of many of the scientific studies which allow us to examine both the individual and population health impact of our New Category products. This evidence is critical to meet the FDA’s burden of proof through the Premarket Tobacco Product Application pathway and a powerful tool for engagement with the broader scientific community. We have an amazing group of scientists and regulatory experts across pre-clinical sciences, clinical sciences, population health sciences, statistics, and electronic publishing & submission that are committed to our vision of A Better Tomorrow and work every day to make that vision a reality.

Not exactly. I had plans for pharmacy school after my undergraduate education; however, after working in a pharmacy throughout college, I realized it was not my preferred career path. I was fortunate to have a great undergraduate advisor in the chemistry department who encouraged me to apply for summer research fellowships. After spending three months in a synthetic organic chemistry lab, I was hooked.

For me, A Better Tomorrow^TM is just a continuation of why I joined Reynolds. It has gone by different names over my 10 years with the company, but an emphasis on attempting to reduce our health impact through the availability of non-combusted alternatives to traditional cigarettes has always been central to our strategy, and the work we do in Regulatory Sciences is critical to realizing this vision.

t has to be my involvement in the team that presented the Camel Snus Modified Risk Tobacco Product Applications to the FDA’s Tobacco Product Scientific Advisory Committee. This was 9 months of preparation to present a clear and compelling case to the committee and resulted in several favorable votes on the applications’ modified risk claims.